Target intelligence / Profile preview

Neuropeptide S (NPS)

Target
NPS
Molecular classification
Other, Peptide neurotransmitter/neuromodulator
01

Overview

Neuropeptide S is a 20-amino acid peptide neurotransmitter that acts as the endogenous ligand for the Neuropeptide S receptor (NPSR), a G protein-coupled receptor. NPS is expressed primarily in a restricted neuronal population in the brainstem (especially near the locus coeruleus), while its receptor is widely expressed throughout the CNS (including the amygdala, subiculum, cortex), and peripherally in tissues such as the airway epithelium. NPS signaling promotes arousal, enhances memory during the consolidation phase, reduces anxiety, and modulates fear extinction. Polymorphisms in NPSR are clinically linked to roles in asthma, anxiety disorders, and rare sleep syndromes. Pharmacologic manipulation of NPSR is under investigation for potential treatments of anxiety, cognitive dysfunction, and inflammatory conditions.

Other names
Neuropeptide SNPSprepro-neuropeptide S
02

Mechanism of action

NPS activates NPSR, a G protein-coupled receptor, promoting cAMP signaling, Ca²⁺ mobilization, and neurotransmitter release (including enhanced glutamatergic transmission). NPSR antagonists block receptor function and consequently NPS-mediated effects.

03

Biological functions

Neurotransmitter/neuromodulation in the CNSRegulation of arousal and wakefulnessFacilitation of memory consolidationAnxiolytic-like effects (reduces anxiety)Modulation of emotional processing and fear extinctionInvolved in immune response (modulation of monocyte migration)
04

Disease associations

Anxiety disorders (e.g., panic disorder)Asthma (via NPSR polymorphisms)Sleep disorders (familial natural short sleep, via gain-of-function NPSR mutations)Neurodegenerative diseases (emerging evidence in models of Alzheimer’s disease)Inflammation (immune modulation)
05

Safety considerations

CNS effects: hyperarousal, anxiety modification, sleep disturbance (in gain-of-function states)Asthma susceptibility via receptor polymorphismsPotential for broader immune or gastrointestinal effects via NPSR expressed outside CNS
06

Interacting drugs

NPSR antagonists (e.g., SHA 68)

2 more in the full profile.

07

Biomarkers

NPSR gene polymorphisms (e.g., N107I variant linked to asthma and altered receptor responsiveness)NPSR1 expression (in CNS or peripheral tissues)

Beyond the preview

Go deeper on Neuropeptide S (NPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuropeptide S (NPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call